 |
SynOx Therapeutics
Last updated: August 01, 2025
CEO - Ray Barlow
Ireland | Funding: $245.9M (+)
Website: https://synoxtherapeutics.com/
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
Website: https://synoxtherapeutics.com/
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
